ABC50: Technology Enhancing Protein and Mono-Clonal Antibody Production
- Technology Application
- Enhancementof therapeutic protein production in mammalian cellsReagentmanufacturing for in vitro diagnostics and research
- Detailed Technology Description
- Technology that enhances levels of protein expression in mammalian cells
- *Abstract
-
The combined market for therapeutic, research and diagnosticproteins is currently more than $100 billionworldwide and rapidly growing. Approximately half of the 140 recombinantproteins currently on the market are produced in mammalian cells. Given therequirement for large amounts of protein and the high costs of upstreammanufacturing processes, the pharmaceutical industry needs technologies thatenhance protein production in mammalian cells.
Dr. Stuart Berger hasdeveloped a proprietary method to boost protein expression and production ofmonoclonal antibodies by as much as 3-fold. The method involves overexpressionof ABC50, a protein involved in the initiation of protein translation. Potential applications of this technologyinclude its use in the generation of cell lines with improved proteinproduction and survival properties for the industrial production ofbiopharmaceuticals.
In addition totherapeutic proteins, Dr. Berger’s technology can be used in other sectors suchas reagent manufacturing for clinical diagnostics (in vitro diagnostics) andlaboratory research.Antibody productionis boosted in ABC50-overexpressing cells. ABC50-overexpressingCHO cells (ABC50) or vector control CHO cells (vector) were cultured inserum-free media for 3 days. Culture supernatants were removed and tested for antibodycontent by ELISA.
- *Principal Investigator
-
Dr. Stuart Berger
- *Publications
- Y. Yu etal, Biochem. Pharmacol, 81 (2011) 488-497.
- Country/Region
- USA
